drugset / Trial / NCT01772836
Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination
Phase 1
Completed
30 enrolled
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
RandomizedParallel-groupDouble-blindTreatment
Summary
RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem to treat bacterial infections, including those due to multi-drug resistant bacteria.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Biapenem | Small molecule | — | Intravenous |
| Subject | Vaborbactam | Small molecule | — | Intravenous |